Washington, DC 20549









Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 21, 2020




Windtree Therapeutics, Inc.

(Exact name of registrant as specified in its charter)









(State or other jurisdiction of

incorporation or organization)



File Number)


(I.R.S. Employer

Identification No.)


2600 Kelly Road, Suite 100, Warrington, Pennsylvania



(Address of principal executive offices)


(Zip Code)


Registrant’s telephone number, including area code: (215) 488-9300


Not Applicable

(Former name or former address, if changed since last report)


Securities registered pursuant to Section 12(b) of the Act: 

Title of Each Class

Trading Symbol

Name of Exchange on Which Registered



Securities registered pursuant to Section 12(g) of the Act:


Common Stock, par value $0.001 per share



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company  ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐





Item 2.02

Results of Operations and Financial Condition.


On January 21, 2020, Windtree Therapeutics, Inc. (the “Company”) disclosed in its Registration Statement on Form S-1 filed with the Securities and Exchange Commission that, based on information currently available, as of December 31, 2019, the Company estimates that cash and cash equivalents were approximately $22.5 million. In addition, the Company believes that, before any additional financings, existing cash and cash equivalents will enable the Company to fund operations into the second quarter of 2021.


These estimates are preliminary and actual results may differ from these estimates due to the completion of the Company’s closing procedures with respect to the fiscal year ended December 31, 2019, the final adjustments and other developments that may arise between now and the time the financial results for the 2019 fiscal year are finalized. As such, these estimates should not be viewed as a substitute for the Company’s full audited financial statements prepared in accordance with U.S. generally accepted accounting principles. These expected results could change materially and are not necessarily indicative of the results to be achieved for the 2019 fiscal year or any future period. As a result, of the foregoing considerations and other limitations described herein, investors are cautioned not to place undue reliance on this preliminary financial information. The Company does not undertake any obligation to publicly update or revise this estimate, except as required by law.


The information disclosed under Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Windtree Therapeutics, Inc.



/s/ Craig Fraser



Craig Fraser



President and Chief Executive Officer


Date: January 24, 2020